Participating Companies:

ABBOTT LABORATORIES
ABGENIX
AMGEN
AVENTIS
BAYER
BRISTOL-MYERS SQUIBB
CELGENE
CELGENE SIGNAL RESEARCH DIVISION
CELL THERAPEUTICS
CYCLACEL
ELI LILLY & CO.
ENCHIRA BIOTECHNOLOGY
GENENTECH
GERON
IMMUNEX
KERYX BIOPHARMACEUTICALS
ILEX ONCOLOGY
KOSAN BIOSCIENCES
MEMORIAL SLOAN KETTERING
MILLENNIUM PHARMACEUTICALS
NATIONAL CANCER INSTITUTE
NOVARTIS
OSI PHARMACEUTICALS
OXIGENE
PFIZER
PHARMACIA
RIBOZYME PHARMACEUTICALS
RIGEL
ROCHE
WHISTLER ASSOCIATES


New Oncology Business Development & Licensing Panel:

The Oncology Licensing & Deal-making Climate for 2002-03

Topics Include:

-Cyclin Dependent Kinases
-Tie-2 Kinase
-EGFRs
-Epothilones
-Antimitotic Agents
-Novel Taxanes
-Proteasome Inhibition
-Ubiquitin Ligases
-Vascular Targeting
-Ribozymes
-COX-2 Inhibitors
-Thalidomide
-Telomerase Inhibition
-Antibodies